Medicale Corp. Reports No Revenue, Facing Financial Struggles Despite Reduced Losses and Expenses

Medicale Corp. (PINK: MCLE)

As of the latest quarterly report dated December 31, 2024, Medicale Corp. has not generated any revenue from its business operations, which focuses on consulting services and dietary supplements. The company continues to struggle financially, posting significant net losses while managing a substantial accumulated deficit.

Key Financial Highlights:

• Net Loss for Q4 2024: $12,680, down from $19,307 in Q4 2023.
• Operating Expenses: Decreased to $10,995 from $19,307 year-over-year, representing a 43% reduction.
• Total Current Assets: Remained constant at $159.
• Total Current Liabilities: Increased to $18,187 from $15,507, primarily due to rising accounts payable and accrued interest.
• Accumulated Deficit: $188,525 as of December 31, 2024.
• Shares Outstanding: 5,920,000 common shares.
• Working Capital Deficiency: Increased to $18,028 from $15,348.
• Convertible Notes Payable: Surged to $93,585 from $83,585, indicating reliance on debt financing.

Positive Aspects:

• Significant reduction in operating expenses, highlighting improved cost management.
• Net loss for Q4 2024 is lower compared to the previous year, indicating a potential trend towards better financial health.

Negative Aspects:

• The company has not yet commenced operations or generated revenue.
• Continued reliance on convertible note financing raises concerns about long-term sustainability.
• Working capital deficit reflects ongoing financial challenges that could jeopardize future operations.
• Management lacks effective internal controls due to limited personnel, posing risks of mismanagement.

Overall, Medicale Corp. is at a critical juncture, with substantial financial liabilities and no operational revenue. While there are signs of reduced expenditure, the path to financial viability remains uncertain without significant capital inflow or a shift in operational strategy.